You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

CLINICAL TRIALS PROFILE FOR CURRETAB

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for CURRETAB

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00064025 ↗	Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus	Completed	National Cancer Institute (NCI)	Phase 2	2004-04-01	This phase II trial is studying how well medroxyprogesterone works in treating patients with endometrioid adenocarcinoma (cancer) of the uterine corpus (the body of the uterus, not including the cervix). Hormone therapy using medroxyprogesterone may be effective in treating endometrioid cancer.
NCT00064025 ↗	Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus	Completed	Gynecologic Oncology Group	Phase 2	2004-04-01	This phase II trial is studying how well medroxyprogesterone works in treating patients with endometrioid adenocarcinoma (cancer) of the uterine corpus (the body of the uterus, not including the cervix). Hormone therapy using medroxyprogesterone may be effective in treating endometrioid cancer.
NCT00577122 ↗	Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer	Completed	Translational Breast Cancer Research Consortium	Phase 2	2007-07-01	The purpose of this study is to evaluate the impact of MPA alone and in combination with low dose oral chemotherapy in patients with ER- and PR- advanced breast cancer.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for CURRETAB

Condition Name

Chart
Table

Condition Name for CURRETAB
Intervention	Trials
Estrogen Receptor-negative Breast Cancer	1
Progesterone Receptor-negative Breast Cancer	1
Recurrent Breast Cancer	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for CURRETAB
Intervention	Trials
Adenocarcinoma	1
Breast Neoplasms	1
Uterine Neoplasms	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for CURRETAB

Trials by Country

Map
Table

Trials by Country for CURRETAB
Location	Trials
United States	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for CURRETAB
Location	Trials
Alabama	1
Pennsylvania	1
Texas	1
North Carolina	1
Massachusetts	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for CURRETAB

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for CURRETAB
Clinical Trial Phase	Trials
Phase 2	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for CURRETAB
Clinical Trial Phase	Trials
Completed	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CURRETAB

Sponsor Name

Chart
Table

Sponsor Name for CURRETAB
Sponsor	Trials
National Cancer Institute (NCI)	1
Gynecologic Oncology Group	1
Translational Breast Cancer Research Consortium	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for CURRETAB
Sponsor	Trials
Other	3
NIH	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.